Forbion Announces Closing Of Public Offering Of Portfolio Company, Argos Therapeutics, Inc.

Published: Feb 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics (“Argos” or “the Company”) has closed its initial public offering. The initial public offering price was $8.00 per ordinary share. Argos' ordinary shares have listed on the NASDAQ Global Market and began trading under the symbol "ARGS" on 7 February 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news